Glofitamab is a bispecific monoclonal antibody designed to target both CD20 on B cells and CD3 on T cells. It is an engineered antibody-based therapeutic used in oncology, particularly for the treatment of certain forms of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Glofitamab is marketed in the United States as Columvi (glofitamab-gxbm) and is administered by intravenous infusion.
Glofitamab is a specialized recombinant bispecific antibody pharmaceutical ingredient. Its manufacture requires mammalian-cell expression, sophisticated purification and extensive analytical characterization. Unlike conventional small-molecule APIs, its quality assessment relies on protein identity, purity, aggregation, charge variants, binding activity and biological potency.
Product Name: Glofitamab
USAN / Nonproprietary Name: Glofitamab-gxbm
Molecule Type: Bispecific monoclonal antibody
Antibody Format: 2:1 T-cell-engaging bispecific antibody
Targets: CD20 and CD3
Drug Class: Bispecific Monoclonal Antibody
Therapeutic Class: Antineoplastic Agent
Therapeutic Area: Oncology / Hematology
Glofitamab simultaneously binds CD20-expressing B cells and CD3-expressing T cells. This brings T cells into close proximity with malignant B cells and promotes T-cell activation and cytotoxic activity against the target cell.
Through this T-cell-engaging mechanism, glofitamab can lead to depletion of CD20-positive B cells, including malignant B-cell populations.
Glofitamab is used for the treatment of eligible patients with relapsed or refractory diffuse large B-cell lymphoma and related large B-cell lymphoma indications, according to applicable regulatory labeling.
Glofitamab is particularly important in the treatment of patients whose lymphoma has progressed after multiple previous lines of therapy. Its bispecific design provides a targeted method of recruiting the patient's own T cells to attack CD20-positive malignant B cells.
Glofitamab is a complex recombinant protein rather than a conventional chemically synthesized molecule. Therefore, it does not have a conventional small-molecule molecular formula or a single fixed molecular weight suitable for routine API specification reporting.
As a biological molecule, its characterization includes molecular size, glycosylation, charge heterogeneity, aggregation state, purity and target-binding properties.
Glofitamab quality evaluation may include:
Glofitamab drug substance and drug product require controlled temperature storage and protection from conditions that may affect protein stability. Exact storage conditions should be based on validated stability data and the applicable approved product specification.
Glofitamab represents an important development in T-cell-engaging bispecific antibody technology. Its dual targeting of CD20 and CD3 provides a mechanism for redirecting T-cell activity toward malignant B cells.
Glofitamab is a CD20 × CD3 bispecific monoclonal antibody developed for oncology applications. It is a recombinant biological therapeutic designed to recruit T cells to CD20-positive malignant B cells. Because of its complex protein structure, quality control requires advanced biologic characterization rather than conventional small-molecule API testing.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |